K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
| Autor: | Yvette L. Kasamon, Guang Haun Tu, Elizabeth Garrett-Mayer, Christina Y. Chia, B. D. Smith, Hua Ling Tsai, Carole B. Miller, Lu Qin, Barbara A. Biedrzycki, Jeanne Kowalski, Kathleen M. Murphy, Richard Jones, Hyam I. Levitsky, Kristen Hege, Thomas Harding, Christopher D. Gocke |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Myeloid Neoplasm Residual medicine.drug_class Fusion Proteins bcr-abl Pilot Projects Cancer Vaccines Tyrosine-kinase inhibitor Article Piperazines hemic and lymphatic diseases Internal medicine Leukemia Myelogenous Chronic BCR-ABL Positive medicine Humans Aged Imiquimod business.industry Myeloid leukemia Granulocyte-Macrophage Colony-Stimulating Factor Imatinib Middle Aged medicine.disease Minimal residual disease Tumor Burden Leukemia medicine.anatomical_structure Imatinib mesylate Pyrimidines Immunology Benzamides Leukemia Myeloid Chronic-Phase Aminoquinolines Imatinib Mesylate Female Immunotherapy business K562 Cells medicine.drug Chronic myelogenous leukemia |
| Popis: | Purpose: Chronic myeloid leukemia (CML) can be responsive to T-cell–mediated immunity. K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing vaccine derived from a CML cell line that expresses several CML-associated antigens. A pilot study was developed to determine if K562/GM-CSF immunotherapy could improve clinical responses to imatinib mesylate (IM) in patients with chronic myeloid leukemia. Experimental Design: Patients with chronic phase CML who achieved at least a major cytogeneic response but remained with persistent, measurable disease despite one or more years on imatinib mesylate were eligible. Each was given a series of four vaccines administered in three-week intervals, with or without topical imiquimod, while remaining on a stable dose of imatinib mesylate. CML disease burden was measured serially before and after vaccination. Results: Nineteen patients were vaccinated, with a median duration of previous imatinib mesylate therapy of 37 (13–53) months. Mean PCR measurements of BCR-ABL for the group declined significantly following the vaccines (P = 0.03). Thirteen patients had a progressive decline in disease burden, 8 of whom had increasing disease burden before vaccination. Twelve patients achieved their lowest tumor burden measurements to date following vaccine, including seven subjects who became PCR-undetectable. Conclusions: K562/GM-CSF vaccine appears to improve molecular responses in patients on imatinib mesylate, including achieving complete molecular remissions, despite long durations of previous imatinib mesylate therapy. Clin Cancer Res; 16(1); 338–47 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|